کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2125316 | 1547228 | 2009 | 9 صفحه PDF | دانلود رایگان |
AimTo evaluate the role of radiofrequency ablation (RFA) as treatment of colorectal cancer liver metastases (CLMs).MethodA PubMed literature search for original articles published until August 2008 was performed. Studies with ⩾40 patients, ⩾18 month median follow-up and reported ⩾3 year overall survival (OS) rates after RFA of CLM were selected for analysis.ResultsThirteen clinical series and 8 non-randomised comparative studies were analysed. Median progression free survival after RFA ranged between 6 and 13 months. Median and 5-year OS after RFA (RFA plus resection) ranged between 24–59 months and 18–40% (36–46 months and 27–30%). Comparative studies indicated significantly improved OS after RFA versus chemotherapy alone, RFA plus chemotherapy versus RFA alone and up-front RFA versus RFA following second-line chemotherapy.ConclusionOur findings support that RFA prolongs time without toxicity and survival as an adjunct to hepatectomy and/or chemotherapy in well-selected patients, but not as an alternative to resection.
Journal: European Journal of Cancer - Volume 45, Issue 10, July 2009, Pages 1748–1756